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Abstract 
Background: The causes of renal dysfunction in children treated for childhood cancers are 
multifactorial and clinical manifestations of dysfunction include hypertension, proteinuria 
and varying degrees of renal insufficiency. This study aimed to determine the different 
residual effects of cancer therapy on the renal system and factors associated with the 
residual effects in children treated for childhood cancers. 
Patients and Methods: The study was a descriptive cross sectional study that assessed 130 
children, between the age of 1 and 18 years, who had completed treatment at Charlotte 
Maxeke Johannesburg Academic Hospital and were being followed up at the paediatric 
oncology clinic of the hospital. 
Results: After a median follow-up post treatment of 2 years, the various manifestations of 
renal dysfunction identified in the survivors included; decreased GFR, hypomagnesaemia, 
hypophosphataemia, proteinuria, haematuria and hypertension. In total, 34 survivors 
(26.15%) had at least one manifestation of renal dysfunction after completing treatment. 
The most prevalent manifestation of renal dysfunction detected was decreased GFR 
(17.69%). Hypomagnesaemia and hypophosphataemia were present in 8 (6.15%) and 6 
(4.62%) of the survivors respectively. Patients who had renal dysfunction pre-treatment 
were three times more likely to have renal dysfunction post-treatment. Ifosfamide, 
Carboplatinum, and nephrectomy were significantly associated with a reduction in GFR  
Conclusion: A significant number of the survivors had a decreased GFR while some of them 
had hypomagnesaemia and hypophosphataemia. There was a strong association between 
pre-treatment and post-treatment renal dysfunction. These findings are very important in 
terms of decision making for individual patients with respect to selecting treatment 
modalities and dosages and also with respect to instituting nephro-protective measures to 
avoid further damage to the kidneys during and after treatment.  
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1. INTRODUCTION 
Cancer is a rare diagnosis in children. In well-resourced settings, the incidence of childhood 
cancer is 110 - 130 per million children per annum (1). Although the South African Children’s 
Tumour Registry has reported an incidence of 600 - 700 new cases of childhood 
malignancies per year, in South Africa accurate figures for childhood cancer are not 
available (2). It is estimated that one in 600 children will develop cancer before they turn 16 
years (3). Due to advances in both cancer therapy and supportive regimes, the prognosis for 
patients with cancer diagnosed under the age of 15 has improved dramatically over the past 
few decades (4). This has resulted in larger numbers of survivors who may now potentially 
present with long term side effects in greater numbers than seen before. 
 
The renal system is just one of the systems in the body that may be affected as a result of 
cancer therapy. The causes of renal complications in children with cancer are multi-factorial. 
They may be due to the malignancy itself or may be secondary to the variety of treatment 
modalities used in treating these patients. These include the chemotherapy, radiotherapy or 
surgery used as the primary therapy or the supportive measures used to treat the inevitable 
complications of intensive chemotherapy (5,6). Common chemotherapeutic drugs 
implicated in causing nephrotoxicity include cisplatin, ifosfamide, high dose methotrexate 
and carboplatin (7-9). 
 
Chemotherapy–induced nephrotoxicity may manifest as acute irreversible renal failure, 
slowly progressive chronic renal failure or as specific defects in renal tubule cell function 
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(10). Clinical manifestations of kidney damage include hypertension, proteinuria and varying 
degrees of renal insufficiency (11). 
Assessment of childhood cancer survivors for late renal sequelae is aimed at detection of 
hypertension or other evidence of chronic renal injury. The Children’s Oncology Group for 
Long Term Follow Up (COG LTFU) guideline recommends baseline screening for 
asymptomatic survivors of potentially nephrotoxic therapy. This includes measuring the 
blood pressure, baseline blood tests including calcium, magnesium and phosphate (CMP), 
urea and creatinine and performing a bedside urinalysis (7). 
The finding of significant proteinuria on urinalysis will prompt concern about renal damage 
from prior therapy or the acquisition of new renal disease. Proteinuria is first detected by 
urinary dipstick, which primarily detects albumin. Abnormal glomerular filtration rate (GFR) 
is most often detected by elevated serum creatinine concentrations. Even mild elevations 
should be noted since as much as 50% of renal parenchymal loss may occur before 
detectable changes in the creatinine occur. Since early renal insufficiency is often 
asymptomatic, screening for proteinuria and or measurement of creatinine may be the only 
way to detect its presence (6,7). 
Since potentially serious long-term renal sequelae may evolve following both single 
measures and additive nephrotoxic effects, long-term monitoring of growth, blood pressure, 
and renal function is mandatory for all paediatric oncology patients. These patients should 
also be counselled to avoid lifestyles that put them at risk for renal injury such as tobacco 
use, excessive non steroidal anti-inflammatory drug (NSAID) use, excessive alcohol 
consumption, and dehydration. In addition, avoidance of obesity and treatment of 
hyperlipidaemia will also offer some renal protective effects (6,7).
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1.1 Literature Review 
Childhood cancers are relatively rare and prognosis has been improving in the last three 
decades as a result of more accurate diagnoses and improved treatment strategies (2). 
During recent years the number of paediatric cancer survivors has considerably increased 
due to better treatment regimens and better supportive care (3). This has resulted in the 
long-term side-effects of the various cancer treatment regimens growing in importance. 
Several systems in the body may be affected including the renal system.  
 
Various manifestations of renal dysfunction associated with anti – cancer treatment have 
been described in the past. The most documented manifestations include; hypertension, 
proteinuria, tubular dysfunction, and varying degrees of renal insufficiency in the form of 
reduced glomerular filtration rate (GFR) (6-14). 
Frequencies of renal impairment in patients treated for childhood cancers have been 
documented in studies from various parts of the world but none reported from South Africa. 
In a single centre Iranian study, Arjmandi-Rafsanjani et al (13) reported a 25.2% rate of renal 
toxicity, including tubular disorders and hypertension. Similarly, Knijnenburg et al (14) 
reported a prevalence of 28.1% of therapy-related renal dysfunction in childhood cancer 
survivors. In both studies, the proportions reflected at least one renal adverse effect or 
elevated blood pressure (BP) in the survivors. Gronroos et al (12) documented a seven year 
follow up of 187 children post stem cell transplant in Finland and reported the finding of 
chronic kidney disease (CKD) in 41% at 1 yr, 31% at 3 yr, and 11% at 7 yr. In a retrospective 
study conducted by Bakr et al (8) in Egypt, the authors reported that about 10% of patients 
with acute kidney injury (AKI) developed CKD. 
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1.1.1 Mechanisms of nephrotoxicity 
There are many possible reasons that the renal system may be affected after a course of 
cancer therapy. The primary disease may directly involve or infiltrate into the kidneys or 
related structures, and tumour lysis syndrome may result from the cancer or following 
treatment. Cancer treatments associated with renal damage later in life include 
chemotherapeutic drugs (ifosfamide, cisplatin, carboplatin, methotrexate), renal 
radiotherapy, and nephrectomy (7,12). Nephrotoxic supportive treatment like amikacin, 
vancomycin, amphotericin B and cyclosporin individually, or in addition to the cancer 
therapy, may cause renal damage (7,12).  
 
Therapy induced nephrotoxicity can manifest as acute renal failure (perhaps even requiring 
some form of renal replacement therapy), slowly progressive chronic renal failure or as 
specific defects in renal tubule cell function (7). Clinical manifestations of kidney damage 
include hypertension, proteinuria and varying degrees of renal insufficiency (7). 
  
In addition, children who undergo stem cell transplantation (SCT) may also develop acute 
renal impairment as a major side effect, often leading to permanent renal failure (15,16). Of 
course, it is often a combination of any, or all, of the above factors that will result in long 
term consequences for the renal system. 
 
Primary disease 
Kidney failure may result from primary tumours of the kidneys such as bilateral Wilms 
tumour or tumours of related structures such as the adrenal glands compressing on the 
renal parenchyma (8). Extra renal tumours compressing on the urinary flow system, or 
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tumours arising from the bladder such as rhabdomyosarcoma, may cause obstructive 
uropathy with resultant deleterious effects on renal function (8,17). Some tumours such as 
lymphomas and leukaemia may invade the renal parenchyma or cause renovascular 
obstruction leading to renal failure (8,17). 
 
Tumour lysis syndrome (TLS) 
Tumour lysis syndrome occurs when tumour cells release their contents into the 
bloodstream, either spontaneously due to rapid tumour cell turnover or due to 
chemotherapy-induced tumour cell lysis (18). Tumour lysis syndrome is seen commonly in 
cancers with a high potential for cell lysis such as high-grade lymphomas, acute leukaemia 
and other rapidly proliferating tumours leading to the characteristic findings of 
hyperuricaemia, hyperkalaemia, hyperphosphataemia, hypocalcaemia and, sometimes, 
acute renal failure (17,18). Acute renal failure usually occurs due to uric acid crystal 
formation in the renal tubules secondary to hyperuricaemia (uric acid nephropathy), calcium 
phosphate deposition related to hyperphosphataemia or a combination of both (18).   
Routine prophylaxis against TLS consists of oral or intravenous allopurinol to block uric acid 
formation coupled with intravenous hydration with or without urinary alkalinisation 
(8,17,18).  
 
Chemotherapy 
a. Ifosfamide 
Ifosfamide (IFO) is an alkylating agent that is used in paediatric treatment protocols of 
lymphomas, rhabdomyosarcoma, soft tissue sarcomas, Wilms tumour, bone sarcomas, germ 
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cell tumours and neuroblastoma (12). The most common manifestation of ifosfamide-
induced nephrotoxicity is proximal tubular dysfunction and, less often, decreased GFR 
(7,19). It may lead to the Fanconi Syndrome including hypophosphataemic rickets and 
proximal renal tubular acidosis. Ifosfamide may also cause any combination of chronic 
glomerular, proximal or distal tubular toxicity (19). Although acute renal tubular dysfunction 
that occurs during therapy often resolves prior to the next course, permanent and 
potentially progressive kidney damage may also occur (7,19).  
 
b. Cisplatin and Carboplatin 
Cisplatin (cis-diamminedichloroplatinum, CIS) is a heavy-metal compound used in the 
treatment of a large number of carcinomas including osteogenic sarcoma, Ewing’s sarcoma, 
hepatoblastoma and germ cell tumours (12). Cisplatin induces acute changes in glomerular 
and tubular function (12). Proximal tubular toxicity causes hypomagnesaemia and 
hypocalcaemia, and glomerular damage can be noticed by reduced GFR (12,20).  Cisplatin 
has been reported to induce long-term reduction in GFR and renal magnesium wasting (12). 
Womer et al (21) found a mean 8% decrease in GFR per 100 mg/m2 dose received. Use of 
CIS concurrently with other nephrotoxic agents, particularly IFO, increases the risk of renal 
injury (22). 
 
Carboplatin (CARBO) is a structural analogue of CIS with a spectrum of activity similar to 
cisplatin. It is less nephrotoxic than cisplatin with myelosuppression being its major dose-
limiting side effect (7). Carboplatin may be also associated with renal magnesium wasting 
and reduced GFR but the changes are less severe than those caused by cisplatin (12). Unlike 
cisplatin it is not transformed into toxic metabolites by renal tubule cells – hence its 
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decreased nephrotoxicity (7). Clinically important reductions in GFR and hypomagnesaemia 
are rare following carboplatin. Paradoxically, it is possible that the risk of renal insufficiency 
and tubulopathies is higher with carboplatin/ifosfamide than with cisplatin/ifosfamide 
combination therapy (22,24). 
 
c. Methotrexate 
Methotrexate (MTX) is a folate agonist that inhibits dihydrofolate reductase, the enzyme 
responsible for converting folic acid to reduced folate cofactors (12). High-dose 
methotrexate (HD-MTX) is commonly used in paediatric oncology in the treatment of acute 
lymphatic leukaemia (ALL), non-Hodgkin lymphoma (NHL), osteosarcoma and certain brain 
tumours (12). High-dose MTX (HDMTX), in which doses in the range of 1000-33,000 mg/m2 
are used in combination with leucovorin, is associated with acute renal dysfunction in 0-
12.4% of patients with an overall incidence rate of 1.8% (25). The mechanism for MTX 
nephrotoxicity is postulated to be precipitation of the drug and metabolites within the renal 
tubular lumen. MTX related nephrotoxicity appears to be reversible, with a median time to 
recovery of renal function of 16 days (range 4-48 days) (25,26). There is a paucity of 
information regarding the long-term renal sequelae associated with MTX. 
 
Radiation Therapy 
Irradiation of the kidney can occur when the primary tumour is located in, or near, the 
kidney. In susceptible patients, radiation nephritis or radiation nephropathy arises after a 
latent period of 3-12 months and is manifest by varying degrees of hypertension, 
proteinuria, renal insufficiency and anaemia (15). Doses less than 18 gray (Gy) to the whole 
kidney appear to rarely cause severe or long-lasting renal injury while doses greater than 20 
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Gy result in significant nephropathy (27). In general, studies have shown that the risk for 
renal insufficiency is higher among children receiving higher doses of radiation (6,15). 
 
Nephrectomy 
Survivors of childhood cancer who have undergone nephrectomy are at risk for various 
complications including renal insufficiency, hyperfiltration injury, hypertension, and 
hydronephrosis (7). Compensatory hypertrophy of the remaining kidney is a well-
documented finding after nephrectomy (28). Although this adaptation may initially increase 
glomerular filtration capacity, glomerulosclerosis and interstitial injury may ultimately lead 
to deterioration of renal function (7,26). For childhood cancer survivors, other nephrotoxic 
insults may also contribute to impaired renal function.  
 
Supportive therapy 
Supportive therapy is required due to prolonged periods of immune suppression from 
aggressive therapy with an increase in risk of nosocomial infections and neutropaenic sepsis 
(12). Some of the agents used include amphotericin B, nephrotoxic antibiotics such as 
amikacin and vancomycin and anti-viral agents such as cidofovir and foscarnet.  Other 
agents such as cyclosporine A, for immunosuppressive therapy following stem cell 
transplantation, are also used. These agents can all cause a reduction in GFR and/or a distal 
tubulopathy with renal salt wasting, hypokalaemia, hypomagnesaemia and a loss of urine 
concentrating ability (12,29).  
 
Amphotericin B is an antifungal agent used as treatment for patients with established or 
suspected fungal infections.  Reported renal side effects include nephrotoxicity and 
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electrolyte abnormalities (hypokalaemia, hypomagnesaemia, and hyperchloraemic 
metabolic acidosis) (30,31). Severe renal failure is less common but the risks increase with 
diuretic-induced volume depletion or the concurrent administration of other nephrotoxins 
such as aminoglycoside antibiotics, cyclosporine A, nephrotoxic cancer chemotherapy and 
foscarnet (31). Amikacin, like other aminoglycosides, causes nephrotoxicity by inhibiting 
protein synthesis in renal cells. This mechanism specifically causes necrosis of cells in the 
proximal tubule, resulting in acute tubular necrosis which can lead to acute renal failure 
(32). Nephrotoxicity is an infrequent (5% of patients), and reversible, adverse effect of 
vancomycin but it may be potentiated by concomitant aminoglycoside therapy (33). The 
exact mechanism of vancomycin induced renal toxicity is not well defined (34). 
Stem cell transplantation (SCT) 
Stem cell transplantation is associated with several late effects, mainly depending on pre-
transplantation conditioning therapy with or without total body irradiation (TBI), 
chemotherapy or organ manifestations of GVHD (12). Total bone irradiation is considered to 
be the principal cause of chronic SCT nephropathy, the clinical onset of radiation-induced 
nephropathy typically developing between 6 and 12 months after irradiation (15). It has 
been reported that 5-28% of paediatric long-term SCT survivors will develop chronic renal 
dysfunction (15,16). Patients treated with SCT have especially high risk for renal impairment 
since they have often already been treated with nephrotoxic drugs before SCT (12). 
 
1.1.2 Evaluation of Childhood Cancer Survivors Treated with Nephrotoxic Therapy 
Assessment of childhood cancer survivors for late renal sequelae is aimed at detection of 
hypertension or other evidence of chronic renal injury. The Children’s Oncology Group Long 
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Term Follow Up (COG LTFU) Guidelines recommend baseline screening for asymptomatic 
survivors of potentially nephrotoxic therapy which include blood pressure measurement, 
serum electrolytes including calcium, magnesium and phosphate, serum urea and 
creatinine, and urinalysis (7). 
 
The primary role of the kidney in the control of blood pressure is related to regulation of salt 
and water excretion in response to changes in extracellular fluid volume, and generation of 
agents which directly increase peripheral vascular resistance (34). Measurement of blood 
pressure as part of the routine physical examination allows detection of abnormal blood 
pressure which may be a pointer to underlying renal problem.  
 
Finding significant proteinuria on urinalysis generates concern about renal damage from 
prior therapy or the acquisition of new renal disease (7). Persistently increased protein 
secretion is usually a marker of kidney damage. Standard urine dipsticks can be used in the 
screening of proteinuria (14). 
 
Although glomerular filtration is only one component of renal function, it is often used as 
surrogate marker to assess overall renal function. Serum creatinine (SCr) is generally used as 
an indirect indicator of glomerular filtration rate (GFR) (7). This is based on the assumption 
that creatinine is primarily eliminated by glomerular filtration and that the production, and 
excretion, of creatinine are believed to be constant. However, a detectable change in the 
SCr is often seen much later after renal damage has occurred (12). Also, calculated GFR is 
most commonly estimated in children by using formulas based on the SCr and height, 
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however these formulae have not been shown to be accurate in all populations of children 
without underlying renal pathology (36,37). 
 
Tubular damage in the kidneys may be accompanied by deranged serum electrolytes 
including magnesium, an alkaline urine pH and increased urinary excretion of phosphate, 
bicarbonate, sodium, potassium, glucose and amino acids. In addition, polyuria and 
hyperuricaemia may also complicate these finding (7,38). 
 
After the baseline evaluation, annual follow-up is recommended (7). Progressive renal 
insufficiency, proteinuria, or hypertension should prompt referral to a nephrologist. Patients 
with a single kidney should be informed about potential risks to the remaining kidney (7). 
Patients at risk for renal sequelae should be counselled to avoid lifestyles that put them at 
risk for renal injury such as tobacco use, excessive NSAID use, excessive alcohol 
consumption, and dehydration. In addition, avoidance of obesity and treatment of 
hyperlipidaemia will also offer some renal protective effects (7). 
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1.2 Justification for the study 
Despite concerted efforts by paediatric oncologists to offer a holistic and comprehensive 
post treatment follow up service, the health of the renal system is often neglected. 
Currently, at CMJAH, routine surveillance includes regular blood tests (full blood count, 
calcium, magnesium and phosphate, and urea, electrolytes and creatinine). However it does 
not always include routine blood pressure monitoring or urinalysis, even in patients known 
to have received nephrotoxic agents.  
 
The serum creatinine, which is used as a marker for renal function, often lags behind 
deterioration in renal function, and significant damage to the kidneys may have already 
occurred before it increases to a point that will generate alarm. 
 
There is little or no data on long term nephrotoxicity among children treated for cancer in 
South Africa and the findings of this study will give us some information on this topic and 
may also determine if changes should be made to the renal follow up protocol in these 
patients.  
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1.3 General aim 
To determine renal side effects in children treated for childhood cancers in CMJAH. 
Specific objectives 
1. To document the different residual effects of cancer therapy on the renal system in 
this group of patients. 
2. To determine the prevalence of these various renal side effects in this group. 
3. To determine the factors associated with the above renal side effects in this group. 
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2. MATERIALS AND METHODS 
2.1 Study Design 
The study was a descriptive cross sectional study conducted at the paediatric oncology unit 
of CMJAH. 
 
2.2 Study population 
Children, between the age of 1 and 18 years, who had completed treatment at CMJAH and 
were being followed up at the paediatric oncology clinic of the hospital. 
 
2.3 Selection criteria 
Inclusion criteria 
Children aged between 1 and 18 years at the oncology clinic at CMJAH who had completed 
treatment and were in remission. 
 
 Exclusion criteria 
1. Children with evidence of renal impairment prior to diagnosis of cancer.                          
2. Children whose parents or caregivers refused consent. 
3. Children who presented to the clinic for unscheduled non routine visits. 
4. Children who fell outside the study age group criteria 
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2.4 Sample size 
The sample size calculated for the study was 206, using the sample size determination for 
proportions (39) and a reference prevalence of a previous study of 15.9% (8). This target 
was not achieved on account of logistics and time constraints. Despite extending the period 
of data collection by 2 months and numerous efforts at calling-in patients, only 130 patients 
were able to be enrolled by the end of the time period allocated to data collection. 
 
2.5 Data collection 
All patients who met the selection criteria were recruited consecutively from the paediatric 
oncology clinic. Patients recruited had a general examination (performed by the principal 
investigator) with emphasis on anthropometry and blood pressure, and findings were 
recorded on a standard patient data capture sheet. Blood pressure was measured using a 
mercury sphygmomanometer. A urine sample was collected for each of the patients and a 
dipstick urinalysis was performed, the findings of which were also recorded on the data 
capture sheet. The data capture sheet was also used to collect patients’ details with regard 
to details on the type of cancer diagnosed and available pre-treatment investigations and 
treatment. All other information about the patients was obtained from the patient records 
in the data base of the oncology unit of the paediatrics department at CMJAH.  
Blood results of samples already routinely sent to the laboratory, as part of the current 
standard follow up protocol of the unit (full blood count, calcium, magnesium and 
phosphate, and urea, electrolytes and creatinine) were retrieved and recorded onto the 
data capture sheet.  
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No time limit in terms of post treatment duration for recruitment of patients was used. 
Patients with abnormal results were referred to the paediatric renal clinic at CMJAH for 
further evaluation. A sample of the data capture sheet used can be viewed in appendix A.   
 
2.6 Definition of renal dysfunction 
We have labelled the presence of any of the following “Renal Dysfunction” namely reduced 
eGFR, hypophosphataemia, hypomagnesaemia, proteinuria, haematuria, glucosuria and 
hypertension. Estimated GFR was calculated using the modified Schwartz formula (36) and 
eGFR <90 ml/min per 1.73m2 was considered as abnormal as recommended by the Kidney 
Disease Outcomes Quality Initiative guidelines (40). Also, serum phosphate and magnesium 
levels of less than 0.9mmol/L and 0.7mmol/L respectively were considered as abnormal. 
Dipsticks for protein, blood and glucose were considered abnormal if they were ≥ 1+ when 
compared with the reference chart. Hypertension was defined by the patient having a 
systolic and/or diastolic blood pressure (BP) that was in the 95th percentile or higher for sex, 
age, and height (41). 
 
2.7 Data analysis 
All data were collated, checked and analysed using the STATA statistical package version 13. 
Continuous variables were described using mean and standard deviation. Categorical 
variables are presented as percentages. Chi Square test and Logistic Regression Analyses 
were used to test for the association between the outcomes and the various exposures. A 
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confidence interval of 95% was used and a p value of less than 0.05 was regarded as 
significant. 
 
 
2.8 Ethics and consent 
Ethical clearance was obtained from the human research ethics committee of the University 
of the Witwatersrand. (Ethics clearance certificate number: M130821) 
 
Informed consent was obtained from the legal guardians of the patients included in the 
study and assent was obtained from children old enough to understand the study.  
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3. RESULTS 
Between October 2013 and May 2014, 130 survivors of childhood cancer were recruited for 
the study. The male to female ratio was 1.13:1. The mean age of the children at the time of 
recruitment was 10.93 years ± 4.65 with a mean height and weight of 138.1cm ± 25.8 and 
39.9Kg ± 21.7 respectively (Table 1). The leukaemias were the most prevalent group of 
childhood cancers treated among the group (Figure 1).   
Table1. Descriptive characteristics of the childhood cancer survivors 
   
Sex n=130 100% 
Male  69 53.08 
Female 61 47.92 
   
Age group (years)   
≤5  20 15.38 
>5 - 10   39 30.00 
>10 - 15   45 34.62 
>15 26 20.00 
   
Age at Diagnosis (years)   
<5  68 52.31 
5 - <10   35 26.92 
10 - <15   24 18.46 
>15 3 2.30 
   
Duration of treatment (months)   
1 – 6 36 27.69 
>6 – 12 41 31.54 
>12 53 40.77 
   
Duration after treatment (years)   
<1 59 45.38 
1 - <5 56 43.08 
>5 15 11.54 
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The prevalence of renal dysfunction 
Thirty four (26.15%) of the cohort had missing/incomplete results (pre-treatment) from the 
clinical records. They were excluded from the analysis. In the remaining patients, who had a 
complete set of records available, the various manifestations of renal dysfunction identified 
(both pre and post treatment) included; reduced glomerular filtration rate (GFR), 
hypomagnesaemia, hypophosphataemia, proteinuria, haematuria and hypertension. In 
addition to the above, glucosuria was also identified as one manifestation of renal 
dysfunction present pre-treatment (Table 2).  
 
In total, 34 patients (26.15%) had at least one manifestation of renal dysfunction after 
completing treatment. The most prevalent manifestation of renal dysfunction detected was 
Leukaemias 
26% 
Lymphomas 
22% 
Renal tumours 
20% 
Sarcomas 
8% 
Germ cell tumours 
8% 
Hepatoblastoma 
4% 
Others  
12% 
Figure 1. Pie chart showing distribution of treated childhood cancers 
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decreased GFR which was present in 23 (17.69%) patients.. Hypomagnesaemia and 
hypophosphataemia were present in 8 (6.15%) and 6 (4.62%) of the patients respectively. 
Proteinuria, haematuria and hypertension had the least prevalence amongst the group 
(Table 2). 
 
The prevalence of any form of renal dysfunction in the group was found to be higher pre-
treatment as compared to the post-treatment (Table 3). The most prevalent form of renal 
dysfunction (both pre-treatment and post treatment) was reduced GFR (34.62% and 17.69% 
respectively).  
 
When comparing the overall prevalence of renal dysfunction, pre and post-treatment, Table 
4 demonstrates that 10 (18.5%) of the children who had no dysfunction prior to treatment 
were found to have at least one renal dysfunction post-treatment. Twenty five (59.5%) of 
the 50 patients who had renal dysfunction pre-treatment had no dysfunction post-
treatment and 17 (40.5%) of those who had renal dysfunction pre-treatment still had at 
least one form of renal dysfunction.  
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Table 2. Prevalence of renal dysfunction in childhood cancer survivors pre-treatment 
 n=130 % 
Renal dysfunction (General)   
No 54 41.54 
Yes 42 32.31 
Data missing 34 26.15 
   
Renal dysfunction (Cumulative)   
No problem 54 41.54 
Single  problem 37 28.46 
2 problems 3 2.31 
3 problems 1 0.77 
4 problems 1 0.77 
Data missing 34 26.15 
   
Individual dysfunctions with proportions   
        eGFR   
Normal 83 63.85 
Low 45 34.62 
Data missing 2 1.50 
Magnesium   
Normal 123 94.62 
Low 3 2.31 
Data missing 4 3.08 
Phosphate   
Normal 123 94.62 
Low 3 2.31 
Data missing 4 3.08 
Urine Protein   
No 124 95.38 
Yes 5 3.85 
Data missing 1 0.77 
Urine Blood   
No 124 95.38 
Yes 6 4.62 
Urine Glucose   
No 129 99.23 
Yes 1 0.77 
        Hypertension   
No 95 73.08 
Yes 5 3.85 
Data missing 30 23.07 
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Table 3. Prevalence of renal dysfunction in childhood cancer survivors post-treatment 
 n=130 % 
Renal dysfunction (General)   
No 96 73.85 
Yes 34 26.15 
   
Renal dysfunction (Cumulative)   
No problem 96 73.85 
Single  problem 29 22.31 
2 problems 4 3.08 
3 problems 1 0.77 
   
Individual dysfunctions with proportions   
        eGFR   
Normal 107 82.31 
Low 23 17.69 
   
Magnesium   
Normal 122 93.85 
Low 8 6.15 
   
Phosphate   
Normal 124 95.38 
Low 6 4.62 
   
Urine Protein   
No 129 99.23 
Yes 1 0.77 
   
Urine Blood   
No 129 99.23 
Yes 1 0.77 
   
Urine Glucose   
No 130 100.00 
Yes 0 0.00 
   
Hypertension   
No 129 99.23 
Yes 1 0.77 
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 There was a significant statistical association between having renal dysfunction in general 
pre-treatment and then having it present post-treatment (p=0.02). Patients who had renal 
dysfunction pre-treatment in general were three times more likely to have renal dysfunction 
post-treatment (OR, 2.99; 95%CI, 1.19-7.53). (Table 5) 
 
Table 4. Renal dysfunction in childhood cancer survivors pre and post-treatment 
 Post-treatment 
 
Pre-treatment 
No Yes Total 
 No 44 10 54 
 Yes 25 17 42 
Missing data 27 7 34 
    Total 96 34 130 
 
 
Table 5. Test of association between renal dysfunction pre and post-treatment, excluding 
the missing data. 
Pre-treatment 
        Post-treatment 
 No Yes Total 
No 44 10 54 
Yes 25 17 42 
Total 69 27 96 
Chi square = 5.64, p = 0.02                OR = 2.99 (1.19-7.53), p = 0.02 
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Table 6. Univariate logistic regression analysis on the outcome variables ( renal dysfunction) 
    
 RENAL DYSFUNCTION 
 Decreased  GFR Hypomagnesaemia Hypophosphataemia 
 n=23/130 n=8/130 n=6/130 
 OR (95%CI) P Value OR (95%CI) P Value OR (95%CI) P Value 
EXPOSURE       
Ifosfamide (no/yes) 2.98 (1.13-7.88) 0.03 2.33 (0.52-10.41) 0.27 3.96 (0.75-20.81) 0.10 
Carboplatinum (no/yes) 3.46 (1.19-10.12) 0.02 _a _a 1.18 (0.13-10.68) 0.89 
Cisplatinum 1.09 (0.28-4.16) 0.12 2.57 (0.47-13.99) 0.28 1.45 (0.16-13.30) 0.74 
Ifosfamide + Carboplatinum (no/yes) 3.15 (1.48-6.71) <0.01 1.05 (0.29-3.74) 0.94 2.31 (0.67-7.89) 0.18 
Ifosfamide + Cisplatinum (no/yes) 1.86 (0.90-3.82) 0.09 2.15 (0.75-6.11) 0.15 2.31 (0.72-7.45) 0.16 
Methotrexate (no/yes) 0.27 (0.09-0.84) 0.02 2.75 (0.63-12.07) 0.18 1.58 (0.31-8.17) 0.58 
Nephrectomy (no/yes) 5.62 (2.10-15.03) <0.01 _a _a _a _a 
TLS (no/yes) 2.39 (0.21-27.5) 0.49 _a _a _a _a 
Radiotherapy (no/yes) 1.03 (0.36-3.21) 0.89 0.53 (0.06-4.48) 0.56 1.98 (0.34-11.43) 0.45 
Amikacin (no/yes)  0.9 (0.34-2.39) 0.83 0.68 (0.13-3.54) 0.65 0.41 (0.04-3.58) 0.42 
Vancomycin (no/yes) 1.45 (0.51-4.11) 0.49 _a _a 0.76 (0.08-6.74) 0.80 
Amphotericin B (no/yes) 2.39 (0.21-27.51) 0.49 _a _a _a _a 
Duration of treatment  (months) 0.96 (0.92-1.01) 0.40 1.03 (0.97-1.08) 0.34 0.99 (0.92-1.06) 0.73 
Duration after treatment (years) 1.26 (1.07-1.47) <0.01 0.60 (0.28-1.27) 0.18 0.78 (0.44-1.39) 0.40 
_a :Not included in the logistic regression because of too few individuals with the exposure or the variable(dysfunction). 
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Table 6 demonstrates the individual exposures as independent risk factors for renal damage 
but only shows the results of the univariate logistic regression analyses for 3 of the outcome 
variables namely decreased GFR, hypomagnesaemia and hypophosphataemia. The 
remaining four variables namely proteinuria, haematuria, glycosuria and hypertension were 
not analysed as they were present in too few survivors to allow for the performance of any 
meaningful statistical analysis. 
 
Table 7. Multivariate logistic regression for decreased GFR. 
                 Decreased GFR    (n=23/130) 
 OR (95% CI) P value 
Exposure   
Nephrectomy 6.22 (1.85-20.98) <0.01 
Carboplatinum 3.97 (1.08-14.55) 0.04 
Ifosfamide 5.06 (1.51-16.92) <0.01 
Duration after treatment (years) 1.20 (1.00-1.44) 0.05 
Methotrexate 0.41 (0.10-1.77) 0.23 
 
 
 As can be seen in Table 6, decreased eGFR was the only outcome that had a significant 
association with some of the exposures. Use of ifosfamide (OR, 2.98; 95%CI, 1.13-7.88), 
carboplatinum (OR, 3.46; 95%CI, 1.19-10.12) and having had a nephrectomy (OR, 5.62; 
95%CI, 2.10-15.03) had the strongest association with reduced eGFR. Survivors who had 
ifosfamide/carboplatinum combination therapy (OR, 3.15; 95%CI, 1.48-6.71) were more 
likely to develop decreased GFR when compared to survivors who had 
ifosfamide/cisplatinum combination therapy (OR, 1.86; 95%CI, 0.90-3.82). Duration after 
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treatment (OR1.26; 95%CI, 1.07-1.47) also had a significant association with decreased GFR. 
Patient who had methotrexate as part of their treatment were less likely to have decreased 
GFR (Table 6). 
 
Table 7 shows a multivariate model of the adjusted exposures significant to decreased GFR. 
In Table 7 we see that decreased GFR was still significantly associated with nephrectomy, 
carboplatin, ifosfamide and the duration after treatment but not with methotrexate. Patient 
who had nephrectomy were six times more likely to have a decreased GFR after treatment 
(Table 7). 
 
No treatment related exposures could be identified for the occurrence of hypomagnesaemia 
and hypophosphataemia. 
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4. DISCUSSION 
The causes of long term renal complications in childhood cancer survivors are multifactorial 
and may be due to the tumour itself, the variety of treatment modalities used to treat the 
cancer treatment and/or nephrotoxic supportive measures used during therapy. The risk of 
developing long term manifestations of renal damage is thought to increase with increasing 
survival rates (4-16). 
 
This study attempted to document, and analyse, the different residual effects of cancer 
therapy on the renal system in a group of post treatment survivors of paediatric cancer at 
CMJAH. 
 
Looking at the breakdown of the primary diagnosis in this cohort of patients, the leukaemias 
were found to be the most prevalent (26%), followed by the lymphomas (22%). This is in 
keeping with the distribution of childhood cancers in general as reported by the South 
African childhood cancer registry (2). 
 
After a median duration following completion of treatment of 2 years, the different 
manifestations of renal dysfunction in this cohort of patients included reduced glomerular 
filtration rate (GFR), hypomagnesaemia, hypophosphataemia, proteinuria, haematuria and 
hypertension.  These findings are similar to renal problems described in previous studies of 
long term outcome of cancer survivors. In these studies, reduced renal function was defined 
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by a decrease in GFR (<90ml/min/1.73m2) and tubulopathies were diagnosed if the patients 
had hypomagnesaemia, hypophosphataemia and/or glucosuria (12-14,42-46). Hypertension 
has also been described by Knijnenburg et al (14) as one of the adverse effects that may be 
present in cancer survivors. 
 
The overall prevalence of renal dysfunction in this study was 26.15%. This falls within the 
range of most studies that looked at the long-term adverse effects of cancer treatment in 
childhood cancer survivors (13,14,42,45). It is much higher than the prevalence recorded in 
the Egyptian study of 15.9% (8). This discrepancy is most likely due to the fact that the 
Egyptian study looked mainly at acute renal problems in the survivors and documented 
acute renal failure as being the most prevalent finding.  The finding of a higher prevalence of 
renal dysfunction than was reported in the Egyptian study further emphasises the need for 
long-term renal follow-up of childhood cancer survivors, as it implies that the risk of renal 
dysfunction may still be present many years after completion of treatment.  
 
Decreased GFR was the most prevalent of all the manifestations of renal dysfunction 
screened for in this study (17.69%). In these patients who had a reduced GFR, all had only a 
minor reduction in GFR (60-90ml/min/1.73m2) or Stage 2 Chronic Kidney Disease as 
described by the National Kidney Foundation (40). Oberlin et al (45) reported a higher 
prevalence of 21.5%. A possible explanation for this difference is that Oberlin’s study 
recruited survivors who were at least five years post completion of treatment and, as stated 
earlier, the longer the survival the more likely the chances of finding some form of renal 
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dysfunction. The Iranian study (13) included patients that were less than 5 years post-
treatment while the Netherlands study (14) recruited patients who were at least 5 years 
post treatment. Both studies reported lower prevalence of decreased GFR of 7.5% and 4.5% 
respectively. Only the Egyptian study (8) reported cases with severe reductions in GFR. 
These were patients who had experienced acute renal failure in the past and now some of 
them (7.6%) needed chronic renal replacement therapy.  
 
Hyphosphataemia and hypomagnesaemia were found in our group but in lower number 
(4.62% and 6.15%) compared to decreased eGFR (17.69%). Although renal phosphate 
wasting has been associated with the use of ifosfamide, (47) no treatment specific 
exposures could be identified. Likewise no factors associated with hypomagnesaemia could 
be identified in this study. Other studies (13,14,42,45,46) did not report a significant finding 
of hyphosphataemia and hypomagnesaemia except for the study by Skinner et al (44). They 
reported a prevalence of hypomagnesaemia of 32% in cisplatin-treated patients and 17% in 
carboplatin-treated patients after a 10 year follow-up.  
Hypertension, proteinuria and haematuria were the least prevalent manifestations of renal 
dysfunction detected in this study and no patient was found to have glucosuria. The Iranian 
and Netherlands study (13,14) both reported significant numbers of cases with hypertension 
and proteinuria, these being the most prevalent of all forms of renal dysfunctions described 
in their survivors. Also, Bardi et al (42) reported proteinuria as the major finding in their 
study. All these studies looked at long term survivors who were at least 5 years post-
treatment. The differences in study population, treatment modality, treatment doses, 
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follow up duration and definition of outcome measures may explain the variations observed 
in the prevalence of the individual outcomes.  
 
To my knowledge, no studies have looked at the presence of renal dysfunction in general 
pre treatment as a risk for renal dysfunction post treatment. About a third of the patients in 
this study had at least one form of renal dysfunction pre-treatment compared to only a 
quarter who had renal dysfunction post treatment. Patients who had renal dysfunction pre-
treatment were three times more likely to have renal dysfunction post-treatment. This is an 
important finding as it implies that patients who have some form of renal dysfunction prior 
to starting therapy need careful long term follow up. 
 
Various exposures were tested for significance with renal dysfunction. Only ifosfamide, 
carboplatinum and nephrectomy were found to be significantly associated with renal 
dysfunction, specifically with a decrease in GFR.  Patients who had been exposed to 
ifosfamide or carboplatinum were three times more likely to have a decrease in GFR while 
patients who had undergone a nephrectomy were five times more likely to have a 
decreased GFR. Patients who had been exposed to combination treatment with 
ifosfamide/cisplatinum were twice as likely to develop renal dysfunction post treatment but 
those exposed to ifosfamide/carboplatinum were three times more likely to develop 
decreased GFR post treatment.  
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After adjusting for the various significant exposures, nephrectomy, carboplatin, ifosfamide 
and the duration after treatment, but not methotrexate, all had an independent impact on 
decreased GFR. Patients who had undergone a nephrectomy were six times more likely to 
have a decreased GFR after treatment. 
 
The risk for renal tubular wasting of phosphate and magnesium increases with increasing 
cumulative dose of certain anticancer drugs, particularly ifosfamide (48,49,19). Stohr et al 
(46) reported an increase risk of 5.6 in patients treated with 24-60g/m2 and an increased risk 
of 18.8 in patients treated with >60g/m2 cumulative dose of ifosfamide. Skinner et al (19) 
also reported a higher prevalence of 20.7% in patients treated with a median dose of 
62g/m2 of ifosfamide. Also, several studies have reported an increase risk of ifosfamide 
induced tubulopathy when combined with a platinum drug (50,51). 
 
Even though in this study the total cumulative doses for the various treatments were not 
estimated, no significant relationship was found between any of the treatment exposures 
and hypophosphataemia and hypomagnesaemia.  
 
Duration after treatment was also significantly associated with GFR. As the duration after 
treatment increased, the likelihood of having reduced GFR also increased slightly. This is in 
keeping with previous studies that showed a higher prevalence of renal dysfunction in long-
term survivors (13,14,42,44,45). 
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Some of the limitations of this study include the fact that the total cumulative dose of anti-
cancer treatment used in the patients was not estimated or associated with the outcomes 
and also that about a quarter of the survivors had missing results/data pre-treatment. 
Another limitation was the inability to clearly ascertain whether the survivors who had renal 
dysfunction pre-treatment and subsequently post-treatment had developed new renal 
dysfunction or just a progression of the existing renal dysfunction.  
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CHAPTER 5. CONCLUSION 
This study describes the various forms of renal dysfunction observed in a cohort of 
childhood cancer survivors post-treatment, their prevalence and their associated factors. A 
significant number of the survivors had a decreased GFR while some of them had 
hypomagnesaemia and hypophosphataemia after a median follow-up post treatment of 2 
years. Less common was the finding of proteinuria, haematuria and hypertension. In 
addition, ifosfamide, carboplatinum, and nephrectomy were significantly associated with a 
reduction in GFR. A significant finding was that of the strong association between pre-
treatment and post-treatment renal dysfunction. Patients with the former were three times 
more likely to have the latter. This is very important in terms of decision making for 
individual patients with respect to selecting treatment modalities and dosages and also with 
respect to instituting nephro-protective measures to avoid further damage to the kidneys 
during and after treatment. Future research on this topic should focus on newly diagnosed 
patients. A prospective follow-up study of children undergoing therapy for childhood 
cancer, with frequent assessment during and after treatment would help clarify many of the 
study limitations alluded to above. Such studies could perhaps include the use of more 
sensitive markers to detect early renal problems as creatinine usually lags behind in 
estimation of renal damage.  
 
Although it is gratifying that the degree of renal dysfunction detected in this study was 
minimal, the high prevalence implies that long-term follow-up in childhood cancer survivors, 
with reasonable attention to the renal system, should be recommended for all survivors of 
childhood cancer and not just those treated for renal tumours. 
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APPENDIX A: DATA COLLECTION SHEET 
Study number         
Sex (M/F)         
Date of Birth         
Diagnosis         
At diagnosis         
Date at diagnosis         
Systolic BP(mm/Hg)         
Diastolic BP (mm/Hg)         
Weight (Kg)         
Height (cm)         
Bicarbonate (mmol/l)         
Creatinine (umol/l)         
Calculated GFR (mL/min/m
2
)         
Calcium (mmol/l)         
Phosphate (mmol/l)         
Urinalysis (Y/N)         
Urine Ph         
Urine Protein         
Urine Blood         
Urine Glucose         
Treatment         
Date started  treatment         
Date completed  treatment         
Ifosfamide (Y/N)         
Cisplatin (Y/N)         
Carboplatin (Y/N)         
Methotrexate (Y/N)         
Amikacin (Y/N)         
Vancomycin (Y/N)         
Amphotericin B (Y/N)         
Cyclosporin (Y/N)         
Radiotherapy (Y/N)         
Nephrectomy (Y/N)         
Bone marrow transplant (Y/N)         
Tumour lysis syndrome(Y/N)         
Renal replacement therapy (Y/N)         
At data capture         
Date of data capture         
Systolic BP(mm/Hg)         
Diastolic BP (mm/Hg)         
Weight (Kg)         
Height (cm)         
Bicarbonate (mmol/l)         
Creatinine (umol/l)         
Calculated GFR (mL/min/m
2
)         
Calcium (mmol/l)         
Phosphate (mmol/l)         
Urinalysis (Y/N)         
Urine pH         
Urine Protein         
Urine Blood         
Urine Glucose         
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